share_log

天茂集团(000627.SZ):2024年上半年实现原保险保费收入246.08亿元

Hubei Biocause Pharmaceutical (000627.SZ): Achieved 24.608 billion yuan in gross insurance premiums received in the first half of 2024.

Gelonghui Finance ·  Jul 11 06:24

On July 11th, Gelonhui reported that Hubei Biocause Pharmaceutical (stock code: 000627.SZ), on the investor platform, stated that in the first half of 2024, China Best Life Insurance will maintain a moderate business scale and continue to promote optimization of its business structure, asset allocation structure, steadily promote asset-liability matching, continuously strengthen the application of new technologies and talent reserves, improve the company's management system, and comprehensively improve the company's operating capabilities. While ensuring that premium income remains stable, according to market conditions, timely adjust business rhythm and structure, vigorously promote the development of long-term value and risk protection-oriented businesses. At present, the business operation of China Best Life Insurance is orderly, moderately stable in scale, and achieved original insurance premium income of 24.608 billion yuan in the first half of 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment